CRESCENT BIOPHARMA, INC. (CBIO) IPO — S-1 Filing, Stock & Insider Activity

CRESCENT BIOPHARMA, INC. IPO — Status & S-1 Filing

Ticker: CBIO
Status: Registered — S-1 filed with the SEC
S-1 filed: 2026-01-07
Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
SEC CIK: 0001253689 · View the S-1 on SEC EDGAR →

Track every registration update on the InsiderAlpha IPO tracker.

Updated Jul 16, 2026 · Last SEC filing 2026-06-23

CRESCENT BIOPHARMA, INC. (CBIO) has filed 12 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-23. 4 Form 8-K material event filings were reported by CBIO in the last 90 days. InsiderAlpha tracks every CBIO SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About CRESCENT BIOPHARMA, INC. (CBIO)

SEC CIK	0001253689

90-Day SEC Filing Activity

Form 4 filings (90d)	12
Form 8-K filings (90d)	4
Latest Form 4 filing	2026-06-23

Recent CBIO Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-22	Lynch Ryan	See Remarks	S — Open-market sale	465	$17.99	$8K	SEC
2026-06-22	Im Ellie Eunkyung	Chief Medical Officer	S — Open-market sale	1.2K	$17.99	$22K	SEC
2026-06-22	McNeill Jonathan	President and COO	S — Open-market sale	20.5K	$17.99	$370K	SEC
2026-06-22	Brumm Joshua T	Chief Executive Officer	S — Open-market sale	42.3K	$17.99	$761K	SEC
2026-06-22	Pinkas Jan	Chief Scientific Officer	S — Open-market sale	1.3K	$17.99	$23K	SEC
2026-06-22	Scalzo Richard William	Chief Financial Officer	S — Open-market sale	1.1K	$17.99	$20K	SEC
2026-06-22	Bispham Barbara Harlin	See Remarks	S — Open-market sale	1.2K	$17.99	$22K	SEC
2025-06-13	BVF PARTNERS L P/IL	10% Owner	J — Other acquisition / disposition	556.6K	—	—	SEC
2025-06-13	BVF PARTNERS L P/IL	10% Owner	J — Other acquisition / disposition	56.1K	—	—	SEC
2025-06-13	BVF PARTNERS L P/IL	10% Owner	J — Other acquisition / disposition	657.3K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for CRESCENT BIOPHARMA, INC. (CBIO). Updated in real time as new filings are submitted to the SEC.

Most-Active CBIO Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Fairmount Funds Management LLC	1	—
Pinkas Jan	1	$23K
Lubner David Charles	1	—
Violin Jonathan	1	—
Balcom Alexandra	1	—

Recent CBIO Form 8-K Material Events

2026-07-15 — Item 8.01, 9.01 [SEC]
2026-07-14 — Item 2.02 [SEC]
2026-06-03 — Item 5.07 [SEC]
2026-04-29 — Item 2.02, 9.01 [SEC]
2026-02-26 — Item 2.02, 9.01 · Earnings · neutral [SEC]
Crescent Biopharma issued a press release on February 26, 2026 announcing financial results for the year ended December 31, 2025. The 8-K provides no detail on the actual results, guidance changes, or whether results beat/missed expectations—only that results were announced. With

Recent Insider Filings

2026-06-23 — Lynch Ryan (See Remarks)
2026-06-23 — Pinkas Jan (Chief Scientific Officer)
2026-06-23 — Scalzo Richard William (Chief Financial Officer)
2026-06-23 — Bispham Barbara Harlin (See Remarks)
2026-06-23 — Im Ellie Eunkyung (Chief Medical Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in CBIO insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

CBIO Insider Trading — FAQ

What is the latest insider trade for CBIO?: CRESCENT BIOPHARMA, INC. (CBIO) had 12 insider filings in the last 90 days, with the most recent on 2026-06-23. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying CBIO stock?: 0 insider purchases of CBIO were filed in the last 90 days.
How many insiders are selling CBIO stock?: 0 insider sales of CBIO were filed in the last 90 days.
Where can I see CBIO SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every CBIO SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live CBIO dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.